# Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Source: https://onco.cc/trials/nct04862663/  
OnCo record `nct04862663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) is a phase 3 interventional study registered as NCT04862663 by AstraZeneca, with 893 participants enrolled, started 2021-05-10 and due to reach its primary completion in 2027-11-01. Interventions recorded: Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04862663
- Phase: 3
- Setting: A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
- Sponsor: AstraZeneca
- Enrolled: 893

## Sources

- ClinicalTrials.gov NCT04862663: https://clinicaltrials.gov/study/NCT04862663

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04862663.json